Navigation Links
ImmunGene's Pipeline of Next Generation Cancer Therapeutics Featured in BioWorld Today
Date:11/11/2010

THOUSAND OAKS, Calif., Nov. 11, 2010 /PRNewswire/ -- ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics with numerous anti-cancer functions built into a single therapy, announced today that a profile of the company and its pipeline is featured in the November 21 issue of BioWorld Today in the NewCo section http://www.bioworld.com/.

The publication noted that, "ImmunGene is currently in advanced partnership discussion with several biotech and pharma companies for its payload... The firm's approach involves fusing a monoclonal antibody with a cytokine, initially interferon, for local delivery to the tumor. Called a CmAb, the molecule can be aimed 'directly where we want it to go,' (CEO Sanjay) Khare said."

The addition of the cytokine means that: "'...our CmAbs can do more [than other antibody arming ADCs] since select cytokines are associated with several desirable anti-tumor functions,' he said. CmAbs also are genetically engineered molecules, which could make them simpler and cheaper to produce. 'There's no multistep manufacturing process,' Khare added."

"Another benefit is that the CmAbs can be dosed at a very low level and still be efficacious. ImmunGene's researchers, for example, have been able to limit interferon activity in CmAb to one-one hundredth of the unfused IFN. By fusing it with an antibody that binds only to tumor cells, that interferon dose is sufficient to initiate cell death. ImmunGene's lead CmAb candidate, IGN002, is a third-generation antibody-fusion drug designed to target CD20-positive tumors, initially going after non-Hodgkin's lymphoma not treatable by Rituxan (rituximab, Genentech Inc./Roche AG and Biogen Idec Inc.)," noted the BioWorld article.

Dr. Sanjay Khare, ImmunGene's Chief Executive Officer said, "We are pleased to receive recognition from a global biotech publication for ImmunGene's pipeline of next generation armed antibodies for cancer. ImmunGene's technology promises several important benefits over existing therapy including increased potency compared to the naked antibody; activity where there is resistance to the antibody, and simpler and less costly manufacturing and lower cost of goods."

About BioWorld Today

BioWorld® Today, the news source of record for the biotechnology industry, is read by biotechnology professionals worldwide for its hard-hitting, objective news reporting. BioWorld Today is delivered via email every business morning, and is also found exclusively online at www.bioworld.com. The BioWorld online web site has been internationally recognized as the most comprehensive resource for strategic biotechnology news and information available today

About ImmunGene, Inc.

ImmunGene is a privately-held, drug discovery and development company, leading the use of tapping the power of the immune system to develop next generation of antibody based therapeutics to treat cancer and infectious diseases. For more information please visit www.immungene.com.


'/>"/>
SOURCE ImmunGene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus
2. Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates
3. Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs
4. Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders
5. Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
6. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2010 Financial Results
7. Reportlinker Adds Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline
8. Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports
9. Updated Pfizer Pipeline Focuses on Value, Unmet Medical Need
10. Reportlinker Adds Electrophysiology Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
11. Reportlinker Adds Prosthetic Heart Valves - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Dec. 7, 2016 A new investigational drug originally ... clinical trials in search of the world,s first treatment to ... of research findings today in the journal Science ... be a watershed moment for millions of people living with ... of Van Andel Research Institute,s Center for ...
(Date:12/7/2016)... 2016 DelveInsight,s, "Janus Kinase 3 ... depth insights on the pipeline drugs and ... 3 (JAK3) Inhibitors. The DelveInsight,s Report covers ... development including Discovery, Pre-clinical, IND, Phase I, ... covers the product clinical trials information and ...
(Date:12/7/2016)... Dec. 7, 2016 Hoovers Research ... performed using the combinational analytical tools. The report ... varied research sources to present unique and reliable ... on the market during the next five years, ... which comprises of sub markets, regional and country ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp ... in and around the greater Phoenix metropolitan region, is announcing a charity event ... mission of the Homeless Youth Connection is to promote community awareness of the ...
(Date:12/7/2016)... ... December 07, 2016 , ... DrugDev again demonstrated its dedication ... one of the early adopters completing EU-U.S. Privacy Shield Certification from the U.S. Department ... on both sides of the Atlantic with a mechanism to comply with EU data ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... treat wrinkles and deep lines by smoothing and tightening the skin of the ... out there to address facial aging with very little downtime, Silhouette Instalift is ...
(Date:12/7/2016)... , ... December 07, 2016 , ... It is vital ... is with useful, properly analyzed data. The team at Beckman Coulter has designed Kaluza, ... 'need for speed' and the need to operate in a GLP (Good Laboratory Practice) ...
(Date:12/7/2016)... ... December 07, 2016 , ... When it came time to blow out his candles on his ... the Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his family ... hospital’s 30th heart transplant recipient. , “He was playing at home, when we got ...
Breaking Medicine News(10 mins):